IntroductionThe Asia-Pacific Hunter Syndrome Treatment Market is witnessing notable advancements with growing awareness of rare genetic diseases, improved diagnostic capabilities, and the emergence of novel enzyme replacement therapies. Hunter syndrome (Mucopolysaccharidosis type II) is a rare X-linked lysosomal storage disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (I2S), leading to the accumulation of glycosaminoglycans […]